| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/16/2023 | — | HC Wainwright & Co. | Maintains | Neutral | |
| 12/16/2022 | 198.82% | SVB Leerink | $6 → $2 | Downgrades | Outperform → Market Perform |
| 12/15/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 11/02/2022 | 647.05% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 1394.1% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 1095.28% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 796.46% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 945.87% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 1244.69% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 1692.92% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 796.46% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 647.05% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 1991.74% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 1394.1% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 2290.56% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 1394.1% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 1991.74% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 1394.1% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 3635.25% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 4083.48% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 2888.2% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 1394.1% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 1543.51% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 2888.2% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 3635.25% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
What is the target price for Axcella Health (AXLA)?
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by HC Wainwright & Co. on February 16, 2023. The analyst firm set a price target for $0.00 expecting AXLA to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Axcella Health (AXLA)?
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by HC Wainwright & Co., and Axcella Health maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Axcella Health (AXLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on February 16, 2023 so you should expect the next rating to be made available sometime around February 16, 2024.
Is the Analyst Rating Axcella Health (AXLA) correct?
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a maintained with a price target of $0.00 to $0.00. The current price Axcella Health (AXLA) is trading at is $0.67, which is out of the analyst's predicted range.